Last updated: February 20, 2026
What is the Drug and Its Therapeutic Area?
The National Drug Code (NDC) 70710-1738 corresponds to Lixisenatide, marketed as Lyxumia (by Sanofi). It is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for type 2 diabetes management. It was first approved by the FDA in 2016.
Market Landscape
Current Market Size
- Global GLP-1 RA market was valued at approximately USD 9.2 billion in 2022.
- Projected compound annual growth rate (CAGR) from 2023 to 2028: 15%.
Key Competitors
| Drug Name |
Brand Name |
Market Share (2022) |
Approval Year |
Pricing (US) per dose |
| Liraglutide |
Victoza |
35% |
2010 |
USD 13-14 |
| Semaglutide |
Ozempic |
40% |
2017 |
USD 13-15 |
| Dulaglutide |
Trulicity |
15% |
2014 |
USD 20-22 |
| Lixisenatide |
Lyxumia |
0.5% |
2016 (remnant market) |
USD 10-12 |
Lixisenatide holds a minor segment primarily due to limited adoption and the presence of better-tolerated, more efficacious drugs.
Regulatory and Market Factors
- FDA approval for Lyxumia was limited to select indications; it did not capture significant market share post-launch.
- European and other markets have limited availability, affecting global sales.
- The rise of once-weekly injections (semaglutide, dulaglutide) limits acceptance of once-daily lixisenatide.
Market Entry Barriers and Opportunities
- Need for head-to-head clinical data comparing lixisenatide with newer agents.
- Potential for combination therapy or biosimilar development.
- Real-world evidence showing benefits in specific patient populations could facilitate niche adoption.
Price Projections
Historical Pricing Trends
- Original list price for lixisenatide was approximately USD 11-12 per dose at launch.
- Discounts and pharmacy benefit manager (PBM) negotiations typically reduce net prices to USD 8-10 per dose.
Short-Term (1-2 Years) Projections
- Market stagnation unlikely due to low current usage.
- Price remains stable unless new formulations or biosimilars enter the market.
- Potential reduction if biosimilar competition emerges in the next 2-3 years.
Medium-Term (3-5 Years) Projections
- After patent expiry (expected around 2030), biosimilar entry could reduce prices by 40-60%.
- For now, no biosimilar launches are announced for lixisenatide.
- Price could decline marginally due to increased competition or payer negotiations, settling in the USD 7-9 range per dose.
Long-Term (5+ Years) Outlook
- Biosimuths and generics could lower prices significantly.
- If the drug secures new indications or is repositioned, pricing may stabilize or increase.
- Market share expansion depends on clinical data and regulatory changes.
Pricing Comparison With Alternatives
| Drug |
Typical Dose Cost (USD) |
Dosing Frequency |
Approval Year |
Market Position |
| Lixisenatide |
USD 8-10 |
Once daily |
2016 |
Niche, limited growth |
| Semaglutide (Ozempic) |
USD 13-15 |
Once weekly |
2017 |
Market leader, preferred formulation |
| Dulaglutide |
USD 20-22 |
Once weekly |
2014 |
Competitive, but more expensive |
Strategic Insights
- Market potential remains limited unless new indications or improved formulations are developed.
- Pricing will depend heavily on regulatory approvals and market penetration.
- Biosimilar competition could significantly impact prices post-2030.
Key Takeaways
- NDC 70710-1738 (Lixisenatide) has minimal current market share amid a crowded GLP-1 RA segment.
- Market size expanding at 15% CAGR; however, participation of lixisenatide remains marginal.
- Current prices hover around USD 8-10 per dose, with potential decline following biosimilar approval.
- Long-term price reductions depend on patent expiry and biosimilar development.
- The drug’s future hinges on repositioning, regulatory changes, and market acceptance.
FAQs
1. When will lixisenatide face biosimilar competition?
Potential biosimilar competitors are unlikely before 2030, aligning with patent expiry and biosimilar development timelines.
2. How does lixisenatide’s price compare to other GLP-1 RAs?
It is generally cheaper (USD 8-10/dose) than semaglutide or dulaglutide, but its market share remains low.
3. What factors could improve lixisenatide’s market position?
New clinical trial data demonstrating superior efficacy, additional indications, or cost advantages could boost adoption.
4. Are there existing biosimilar candidates for lixisenatide?
No biosimilar candidates are currently approved or in late-stage development.
5. How will regulatory changes influence price projections?
Approval of biosimilars or changes in reimbursement policies could accelerate price reductions.
Sources
[1] Grand View Research. (2022). Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Market Size, Share & Trends.
[2] IQVIA. (2023). Prescription Data and Market Insights.
[3] U.S. Food and Drug Administration. (2016). Lyxumia Regulatory Approval Documents.
Note: Data reflects publicly available estimates as of early 2023.
